Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Beam Therapeutics (BEAM) over the last 6 years, with Q3 2025 value amounting to 0.4%.

  • Beam Therapeutics' Return on Capital Employed fell 2300.0% to 0.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4%, marking a year-over-year decrease of 2300.0%. This contributed to the annual value of 0.38% for FY2024, which is 2300.0% down from last year.
  • Per Beam Therapeutics' latest filing, its Return on Capital Employed stood at 0.4% for Q3 2025, which was down 2300.0% from 0.36% recorded in Q2 2025.
  • Beam Therapeutics' Return on Capital Employed's 5-year high stood at 0.15% during Q1 2024, with a 5-year trough of 0.65% in Q1 2021.
  • Its 5-year average for Return on Capital Employed is 0.32%, with a median of 0.34% in 2023.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first surged by 4300bps in 2022, then plummeted by -2800bps in 2024.
  • Over the past 5 years, Beam Therapeutics' Return on Capital Employed (Quarter) stood at 0.36% in 2021, then rose by 15bps to 0.3% in 2022, then surged by 50bps to 0.15% in 2023, then plummeted by -188bps to 0.43% in 2024, then grew by 8bps to 0.4% in 2025.
  • Its last three reported values are 0.4% in Q3 2025, 0.36% for Q2 2025, and 0.38% during Q1 2025.